Four Days in Lille: Noventure at ESPGHAN 2026
Our team met paediatric gastroenterologists from across Europe to talk barrier-based care for acute diarrhoea.
Last week, Noventure took part in the 58th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), held from 24 to 27 June 2026 at the Lille Grand Palais. Our team Tomás Bernabeu, Félix Berrocal, Lina Ciranna, and Aleix Cuenca presented the Tasectan® paediatric range at stand #29, engaging in conversations with paediatric gastroenterologists, researchers, and industry partners from across Europe and beyond.
Stand #29: The Tasectan® Range
Visitors explored the full Tasectan® range AF and AF Kids, built on a barrier effect mechanism that protects the intestinal mucosa without systemic absorption; Duo, combining gelatin tannate with tyndallized lactic bacteria; and Hydro, completing the approach with oral rehydration support. All products in the range are CE-marked medical devices, offering a non-pharmacological option at a time when antimicrobial stewardship in children remains a clinical priority.
A Shared Goal: Better Care for Children with Acute Diarrhoea
Throughout the four days, conversations with clinicians confirmed a clear trend: growing interest in mucoprotective approaches to acute gastroenteritis, with barrier-based therapies increasingly considered a practical option in everyday paediatric care. Congresses such as ESPGHAN are where that recognition is built through direct dialogue with clinicians and visibility alongside the field’s leading voices.
Thank You to Everyone Who Visited Stand #29
We thank every clinician, researcher, and partner who stopped by during ESPGHAN 2026. These conversations help shape the next generation of paediatric solutions.
